Triple negative breast cancers (TNBC), i.e., lacking of ERα66, progesterone receptor (PR) and epidermal growth factor receptor (EGFR), are very aggressive tumors with high recurrence, elevated mortality rates and limited therapeutic options. Here, PGR is linked to triple-negative breast carcinoma.